{"id":"NCT03933449","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study","officialTitle":"A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-29","primaryCompletion":"2019-02-13","completion":"2022-03-14","firstPosted":"2019-05-01","resultsPosted":"2020-02-26","lastUpdate":"2023-03-29"},"enrollment":123,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Esophageal Carcinoma","Esophagogastric Junction Carcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"pembrolizumab","otherNames":["KEYTRUDA速","MK-3475"]},{"type":"DRUG","name":"paclitaxel","otherNames":["TAXOL速"]},{"type":"DRUG","name":"docetaxel","otherNames":["TAXOTERE速"]},{"type":"DRUG","name":"irinotecan","otherNames":["CAMPTOSAR速"]}],"arms":[{"label":"Pembrolizumab","type":"EXPERIMENTAL"},{"label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"In the China extension study, Chinese participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that has progressed after first-line standard therapy will be randomized to receive either single agent pembrolizumab or the Investigator's choice of chemotherapy with paclitaxel, docetaxel, or irinotecan.\n\nThe primary extension study hypothesis is that treatment with pembrolizumab will prolong overall survival (OS) as compared to treatment with chemotherapy.","primaryOutcome":{"measure":"Overall Survival (OS) in All Participants","timeFrame":"From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)","effectByArm":[{"arm":"Pembrolizumab","deltaMin":8.4,"sd":null},{"arm":"Chemotherapy","deltaMin":5.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0015"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":19},"locations":{"siteCount":23,"countries":["China"]},"refs":{"pmids":["34973513"],"seeAlso":["http://merckoncologyclinicaltrials.com/"]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":62},"commonTop":["Anaemia","White blood cell count decreased","Weight decreased","Hypoalbuminaemia","Diarrhoea"]}}